A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

Not Applicable

Completed

• Conditions: Multiple Sclerosis; Nervous System Diseases; Multiple sclerosis

• Registration Number: ISRCTN66678006
• Lead Sponsor: ovartis Pharmaceuticals Ltd (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-26
• Study Completion: 2012-12-01
• Last Update Posted: 30 April 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Patients with RRMS by 2005 MacDonald criteria
2. Patients initiated on DMT for the first time after 1 January 2008 and at least 36 months before date of screening for inclusion
3. Patients who consent to complete the questionnaire and for their medical records to be reviewed for the purposes of healthcare research
4. Patients who are able to complete the study questionnaires or have a carer who is able and willing to record the patient?s responses to the study questionnaires

Exclusion Criteria

1. Patients who are unwilling or unable to provide patient consent
2. Patients who are unable to complete the study questionnaires themselves and have no appropriate carer able and willing to assist them

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To describe the number of documented relapses experienced by patients with MS in the first 3 years following DMT initiation

Secondary Outcome Measures

Name	Time	Method
1. To describe the number of documented relapses experienced by patients with MS in the 3 years following DMT initiation by severity<br>2. To describe the DMT prescribing patterns in the first three years following DMT initiation<br>3. To compare clinician-documented and patient-reported relapse symptoms<br>4. To describe the change in patient contact with health care professionals resulting from relapse<br>5. To describe the financial impact of a relapse on patients with MS<br>6. To describe the impact of a relapse on patients? attitudes to DMT